Merck Gets CHMP Positive Opinion for V920 Ebola Zaire Virus Vaccine
18 Outubro 2019 - 8:37AM
Dow Jones News
By Colin Kellaher
Merck & Co. (MRK) on Friday said the European Medicines
Agency's Committee for Medicinal Products for Human Use recommended
approval of the V920 investigational vaccine for the Ebola Zaire
virus.
The Kenilworth, N.J., drug maker said V920, if approved by the
European Commission, would be authorized under the brand name
Ervebo and indicated for active immunization of individuals 18
years of age or older.
The European Commission generally follows the CHMP's
recommendations.
The U.S. Food and Drug Administration last month accepted and
granted priority review to Merck's biologics license application
for V920.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
October 18, 2019 07:22 ET (11:22 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Merck (NYSE:MRK)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Merck (NYSE:MRK)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024
